Rezolute Awaits FDA Feedback on Congenital Hyperinsulinism Drug After Mixed Phase 3 Results
Event summary
- FDA review of Rezolute's Phase 3 sunRIZE study results for congenital hyperinsulinism remains ongoing without a clear timeline.
- Open-label extension phase shows high retention and reduced use of background therapies, suggesting long-term benefits.
- Phase 3 upLIFT study for tumor HI is enrolling patients with topline results expected before year-end 2026.
The big picture
Rezolute's situation highlights the challenges of developing treatments for ultra-rare diseases, where clinical trial design and regulatory expectations can significantly impact approval pathways. The company's focus on refractory hypoglycemia positions it in a niche market with high unmet medical needs, but success hinges on navigating FDA's evolving stance on clinical endpoints and data requirements.
What we're watching
- Regulatory Pathway
- Whether FDA will accept the submitted data as sufficient for a regulatory path forward or require additional trials.
- Long-term Efficacy
- The pace at which open-label extension data will demonstrate sustained glycemic control and clinical benefit.
- Tumor HI Potential
- How upLIFT study results will impact the broader commercial potential of ersodetug beyond congenital HI.
Related topics